Brokerages see up to 20% upside in Cipla post Q1 results; time to buy?

August 1, 2022

Cipla is on track to launch key products, such as gAdvair, gAbraxane, gRevlimid and three peptide products over FY23-24, it said, adding that the US sales run-rate will improve from H2FY23, and barring COVID-19, sales performance in India continues to be robust. The brokerage firm expects a revenue CAGR of 13 per cent, an EBITDA CAGR of 21 per cent and a PAT CAGR of 28 per cent over FY22-24E.

More To Explore

Bullish on Adani group? GQG raises stakes in 3 stocks even as FIIs cut back in market crash

GQG Partners, long bullish on the Adani group, modestly raised stakes in key companies during the March quarter despite mixed stock performance. It increased holdings

April 15, 2026

BofA Securities initiates coverage on Groww with ‘buy’ rating; shares rally 4% to record high. Here’s what the brokerage said

Groww shares hit a new 52-week high. BofA Securities initiated coverage with a Buy rating. The brokerage sees strong growth potential for Groww. It expects

April 15, 2026

Advertiser Disclosure

Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.

Disclaimer

It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information.

The information on this website does not constitute investment advice or a recommendation or a solicitation to engage in any investment activity. This website and its content are not intended for residents of the UAE, US, Canada, Australia, UK, Russia, North Korea, China, Japan, Hong Kong, Singapore and Iran.

Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003